Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Therapeutical antibodies > mepolizumab
mepolizumab
Wednesday 24 November 2004
Mepolizumab is an anti-IL5 monoclonal antibody.
D. Systemic pathology
- Immune system diseases
- Ageing
- Endocrine systemic anomalies
- Environmental and occupational diseases
- Genetic and developmental anomalies
- Hematopathology
- Infectious diseases
- Nutritional diseases
-
Toxics and drugs
-
Therapeutics
- Therapeutic vaccines
- Targeted therapy
- Gene therapy
-
Therapeutics
- Vascular anomalies
Also in this section
- nivolumab
- blinatumomab
- lambrolizumab
- pertuzumab
- cantuzumab
- teplizumab
- panitumumab
- eculizumab
- etanercept
- adalimumab
Keywords
- Therapeutics
